Approach for RNAi-focused Silence Therapeutics sees shares rocket
This article was originally published in Scrip
Executive Summary
Silence Therapeutics' shares opened at 12.5 pence on 7 September, up 75% on the previous day's opening price, after the company announced that it had been approached by an undisclosed company.